Menu Display

Breadcrumb

Media

U.S. News Room

Press Releases

News, Events, Updates, Breakthroughs

Journalists may direct questions to jennifer.brennan@daiichisankyo.com. Or click here for direct contact information for Daiichi Sankyo U.S. Public Affairs team

Press announcements are archived by release date, searchable by topic:

May 28, 2026 NEW
Daiichi Sankyo Showcases Progress Across Industry-Leading Oncology Portfolio with Latest Research Updates at ASCO Download
May 22, 2026 NEW
Datroway Approved in the US as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates Download
May 15, 2026
Enhertu Approved in the US for Two New Indications for Patients with HER2 Positive Early Breast Cancer Download
May 11, 2026
Daiichi Sankyo Unveils New Five-Year Business Plan Focused on Oncology Leadership and Innovation Download
April 13, 2026
Ifinatamab Deruxtecan Granted Priority Review in the US for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapy Download
March 09, 2026
ENHERTU Granted Priority Review in the US as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer Download
March 09, 2026
Patent Dispute Between Daiichi Sankyo and Seagen has Concluded
February 19, 2026
Daiichi Sankyo Appoints John Tsai, MD as Global Head of R&D Download
February 04, 2026
DS3790 Enters Clinical Development as First DXd ADC in Hematology from Industry-Leading ADC Portfolio of Daiichi Sankyo Download
February 03, 2026
DATROWAY Granted Priority Review in the US as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy Download
Page 1 of 20
10 Items per Page
Showing 1 - 10 of 197 results.